Five Professional Stock Trading Rules That Will Make You Successful In Any Market (PDF Version)

Posted on by The INO.com Team

I wanted to thank you personally for doing business with our company. I have just published a book, titled "Five Professional Stock Trading Rules That Will Make You Successful In Any Market".

The book is available right now and it's free. As you are a valued Trader's Blog reader, I wanted you to be among the first to read it.

I hope you enjoy my book, as it was a lot of fun writing and creating it. The book can be easily downloaded (file size 92 megs, it will take few minutes to download) and read in a short time and will provide you with a lifetime of solid trading advice. It will also provide you with a great foundation on which to build your future and your fortune in these interesting times.

Enjoy and every success,
Adam Hewison
Co-founder of the Marketclub

What Moves Biotech Stocks? Ed Arce Has Answers.

Posted on by admin

The Life Sciences Report: Your experience is very broad. Just four or five years ago, you were a big pharma analyst at a major investment bank, where you followed the largest drug makers in the world. From your perspective today, as an analyst following small-cap biotech and medtech, can you talk about the clinical assets that drive value in smaller companies?

Ed Arce: From a market perspective, the key value drivers largely remain the same. First, and by far most important, are the clinical data. The stronger the efficacy, the better. But meeting clinical endpoints needs to translate into a clinically meaningful benefit. An outright therapeutic cure is optimal, but is also quite rare. Also, the overall safety and tolerability profile of any new therapeutic must be commensurate with the severity of the disease, and comparable to the risk profiles of any existing pharmacotherapies. Risk/benefit is obviously a trade-off. The U.S. Food and Drug Administration (FDA), in attempting to balance the risk/benefit equation, has leaned a bit in one direction or the other over the years.

The second point, from a market perspective, is the size of the patient population and the degree to which that population has been, or is, treatment nave.

The third point is value driven by a long product life, in the form of a long-dated patent suite, as well as any regulatory exclusivity offered to the drug. Continue reading "What Moves Biotech Stocks? Ed Arce Has Answers." →

MarketClub TV for 10/18/12: It's official, the US is now spending $1,000,000,000,000 in welfare payments!

Posted on by The INO.com Team

Hello traders everywhere! Adam Hewison here, co-founder of MarketClub with your mid-day market update for Thursday, the 18th of October.

It's hard to believe or even fathom that the United States should be paying over $1 trillion a year in welfare benefits. This is an unsustainable number by anyone's math.

Because of this massive expenditure, we're going to see gold skyrocket as paper money becomes worth less and less when reality sets in.

If you were around in the 70's and thought inflation was bad then, it's going to pale in comparison to what's coming up. The only value will be held in land, gold, and raw commodities that can be traded on a barter system.

I hate to sound so negative, but the reality is we did this to ourselves and have no one else to blame. Continue reading "MarketClub TV for 10/18/12: It's official, the US is now spending $1,000,000,000,000 in welfare payments!" →

Brent Cook and Quinton Hennigh Use Geology to Find Winners

Posted on by admin

The Gold Report: Brent, Quinton recently joined Exploration Insights. What does Quinton bring to the publication?

Brent Cook: Quinton is a geologist who can see the big picture. He focuses on how a mineral deposit forms and assesses if it is economic. His contributions allow us to cover a lot more ground in the same time and our discussions often refine and improve the final investment decisions. It's a whole aspect to the business that's going to help me make Exploration Insights better. Given the state of the junior mining sector, this is the time to be picking up the deposits and companies that are undervalued or that show potential value based on a real economic evaluation.

"Because this is such a high-risk game, we're mostly looking for homeruns."

Quinton came out of Newmont Mining Corp. (NEM:NYSE) and Newcrest Mining Ltd. (NCM:ASX). He knows how the big companies work and what their investment criteria are. Ultimately, our goal at Exploration Insights is to identify deposits that are going to have high enough margins and be large enough to attract a buyout or purchase from a major mining company. Quinton did that at Newmont. Continue reading "Brent Cook and Quinton Hennigh Use Geology to Find Winners" →

Bruno del Ama: Do ETFs Offer Value for MLPs?

Posted on by admin

The Energy Report: Bruno, since Global X Funds brought its first exchange-traded fund (ETF) to market in 2009, you have added another 30, the latest being the Global X MLP ETF (MLPA:NYSE). What is the appetite among investors for ETFs, and specifically those featuring master limited partnerships (MLPs)?

Bruno del Ama: Investors continue to migrate to the ETF asset class, and we are big fans of energy MLPs. Energy transportation is an infrastructure play with a couple of benefits. First, it provides significant diversification to complement investors' portfolios; second, it provides income in a low-interest rate environment.

ETFs are an innovation in the MLP asset class. We at Global X focus on asset classes where we are the first provider of a particular ETF. In our last interview, for example, we talked about our uranium ETF, which provides focused exposure to that market in a way that did not exist before. Innovation is in our DNA. Continue reading "Bruno del Ama: Do ETFs Offer Value for MLPs?" →